Events like the 𝘖𝘯𝘤𝘰𝘭𝘰𝘨𝘺 𝘛𝘳𝘢𝘯𝘴𝘧𝘰𝘳𝘮𝘈𝘡𝘪𝘰𝘯 𝘚𝘶𝘮𝘮𝘪𝘵, hosted today by AstraZeneca in Madrid, are essential for sharing knowledge and fostering collaboration across the oncology community. With a focus on the latest advances in drug development and how to enhance clinical practice through innovative technologies, the event brought together key stakeholders driving the future of #cancercare. This year, our Medical Advisor Almudena Fuster Matanzo represented Quibim in the session “AI in Clinical Practice: Success Stories”, joining Siemens and Sycai Medical to highlight disruptive imaging solutions. It was a great opportunity to showcase how innovative tools can unlock the full potential of imaging data and help shape a future where technology and medicine work seamlessly together to transform cancer care. #OncologyInnovation #AIinHealthcare #MedicalImaging
🇫🇷 We are looking forward to participate in the 73rd JFR (Journées Francophones de Radiologie) in Paris, which will take place from October 3-6. This is a great opportunity to explore how AI is transforming medical imaging, improving precision, and optimizing #patientcare. Don’t miss Prof. Philippe PUECH's pitch, "QP-Prostate® : Optimiser la détection du cancer grâce à l´IA", on Friday, October 3rd at 15:05 in the Forum IA. And visit us at booth FIA-10 to meet our experts—Paul Idelson, Javier Pizcueta Pastor and Claire Palacin—who will be happy to show you our AI solutions and discuss how advanced image analysis can help radiologists in their daily practice. 📆 Don't forget to book a demo: https://lnkd.in/dZJjS_aH #JFR2025 #Radiology#AIinHealthcare #MedicalImaging #InnovationinHealthcare
🏆 Excited to share that Quibim has been recognized as one of the Best Small & Medium Workplaces in Europe 2025! A huge thank you to our incredible team of quibimers—your passion and dedication are what make this truly a #GreatPlaceToWork! Great Place To Work #TeamCulture #gptw #BestInEurope #GreatPlacetoWork #EuropesBestWorkplaces25
In the healthcare sector, certifications go far beyond regulatory checkboxes - they are a guarantee of safety, performance and trust for both patients and professionals. Josep Hortigüela, Senior Vice President of Quality Assurance and Regulatory Affairs, took to the stage at the 𝐈 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐃𝐞𝐯𝐢𝐜𝐞𝐬 𝐅𝐨𝐫𝐮𝐦 in Madrid to share Quibim's regulatory journey. In his talk, “𝘔𝘦𝘥𝘪𝘤𝘢𝘭 𝘚𝘰𝘧𝘵𝘸𝘢𝘳𝘦. 𝘊𝘌 𝘊𝘦𝘳𝘵𝘪𝘧𝘪𝘤𝘢𝘵𝘪𝘰𝘯. 𝘒𝘦𝘺 𝘗𝘰𝘪𝘯𝘵𝘴 𝘢𝘯𝘥 𝘓𝘦𝘴𝘴𝘰𝘯𝘴 𝘓𝘦𝘢𝘳𝘯𝘦𝘥”, Josep reflected on Quibim's path —three CE certifications under the MDR and three FDA clearances for AI-based SaMD solutions—to reveal what it truly takes to bring certified medical software to market. He emphasized the critical factors for compliance, including lifecycle standards and clinical evaluation, as well as cybersecurity, quality management, and realistic timelines, all essential for delivering safe and effective AI solutions in healthcare. FARMAFORUM 2025 #MedicalDevices #SaMD hashtag#HealthcareInnovation #RegulatoryAffairs #MedTech #PatientSafety
🎗️ 1 in 8 men will be diagnosed with #ProstateCancer during their lifetime, and although localized cases have a five-year survival rate of nearly 100%, this figure drops to 32% when the disease spreads. In a recent pharmaphorum article, our CEO & Co-Founder Ángel Alberich-Bayarri explores how AI-generated images can transform prostate cancer care, enabling earlier detection, reducing unnecessary biopsies, and offering more personalized treatment. Awareness is important. But innovation is what will change outcomes. https://lnkd.in/ddYj5qqR #ProstateCancerAwareness #AIInHealthcare #MedicalImaging #CancerCare
We’re always excited to see advancements in prostate cancer detection that don’t require invasive biopsies. In honor of #ProstateCancerAwarenessMonth, we’re pleased to share this study on a promising noninvasive urine test that identifies prostate cancer using three biomarkers: TTC3, H4C5, and EPCAM. The test detects #ProstateCancer with 91% accuracy, even in PSA-negative patients, and can distinguish cancer from benign conditions like BPH and prostatitis. By reducing unnecessary biopsies, it represents a major step toward safer, earlier, and more precise diagnoses. It’s encouraging to see science opening new paths to earlier, safer, and more precise diagnoses. You can read the full paper here: https://lnkd.in/dtM6gViW #EarlyDetection #MedicalInnovation #HealthcareResearch
Our team members Marta Martinez Calle, Ph.D. and Cristina Lerma Arce are currently participating in the 2025 Annual Conference of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) in Barcelona, Spain. Come by booth #SP02 to learn more about QP-Insights, and don't forget to attend Marta's presentation tomorrow, September 16, from 10:00 to 11:00 a.m., where she will discuss in detail our abstract accepted for this conference: “𝘐𝘯𝘵𝘦𝘳𝘷𝘦𝘯𝘵𝘪𝘰𝘯𝘢𝘭 𝘙𝘢𝘥𝘪𝘰𝘭𝘰𝘨𝘺 𝘐𝘮𝘢𝘨𝘪𝘯𝘨 𝘗𝘭𝘢𝘵𝘧𝘰𝘳𝘮 𝘵𝘰 𝘧𝘰𝘴𝘵𝘦𝘳 𝘔𝘶𝘭𝘵𝘪-𝘐𝘯𝘴𝘵𝘪𝘵𝘶𝘵𝘪𝘰𝘯𝘢𝘭 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘚𝘵𝘶𝘥𝘪𝘦𝘴 𝘢𝘯𝘥 𝘊𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘛𝘳𝘪𝘢𝘭𝘴”. What a great opportunity to interact with colleagues, share knowledge, and advance research in interventional radiology. #CIRSE2025 #InterventionalRadiology #MedicalImaging #ClinicalResearch #QPInsights
Quibim will be participating in the European Society of Urogenital Radiology (ESUR) 2025 in Stockholm, September 25–28. Our team — Lara Hernández, Andrea Lorenzo Polo, and Paul Idelson — will be there to connect, share insights, and explore the latest in urogenital imaging. Don’t miss our Industry Symposium along Philips "𝘘𝘗-𝘗𝘳𝘰𝘴𝘵𝘢𝘵𝘦: 𝘈𝘥𝘷𝘢𝘯𝘤𝘪𝘯𝘨 𝘱𝘳𝘦𝘤𝘪𝘴𝘪𝘰𝘯 𝘔𝘙𝘐 𝘢𝘯𝘥 𝘥𝘦𝘤𝘪𝘴𝘪𝘰𝘯 𝘴𝘶𝘱𝘱𝘰𝘳𝘵 𝘧𝘰𝘳 𝘦𝘢𝘳𝘭𝘺 𝘱𝘳𝘰𝘴𝘵𝘢𝘵𝘦 𝘤𝘢𝘯𝘤𝘦𝘳 𝘥𝘦𝘵𝘦𝘤𝘵𝘪𝘰𝘯", with Prof. Philippe PUECH from CHU de Lille, France. 📅 Friday, September 26 ⏰ 12:00 – 12:30 p.m. 📍 Room C1 + C2 Looking to see our solutions in action? Book a demo and discover how we can transform imaging together: https://lnkd.in/dM9kffFj #ESUR2025 #UrogenitalImaging #MedicalInnovatio
At Quibim, we’ve always believed medical images hold far more information than meets the eye. Today, after major collaborative research, we’re proud to share a milestone published in European Radiology: our latest systematic review and meta-analysis, covering data from over 45,000 non-small cell lung cancer (NSCLC) patients, shows that AI applied to routine chest CT scans can predict key tumor mutations such as EGFR, ALK, and KRAS. This finding has the potential to support treatment decisions by prioritizing patients with the highest mutation likelihood, minimizing delays in targeted therapies, and optimizing healthcare resources without compromising quality. We’re deeply grateful to our incredible team and partners who made this breakthrough possible. This is just the beginning of transforming everyday medical images into powerful tools for precision oncology. https://bit.ly/4mcUpU2 #AI #mutationstatus #NSCLC #Medicalimaging #radiomics #lungcancer #radiology
📍 We're live at the 42nd World Congress of Endourology and Urotechnology (WCET) in Phoenix! Come meet our experts—David Bazaga, Nathan Clark, Joshua Moss, Edward Ramirez R.T. (R)(MR) B.S., and Eric Draper—to discover how AI is advancing the treatment of #ProstateCancer, enabling precision in fusion biopsy and focal therapy, and transforming clinical decision-making. Don't miss the opportunity to see our solutions in action—visit us at our booth. Book a demo: https://lnkd.in/dGsVHEhf #WCET2025 #Urology #AIinHealthcare #MedicalImaging #HealthcareInnovation
